Evron JM, et al. - Since January 2010, when HbA1c was initially recommended for screening and diagnosis, researchers assessed how prediabetes and diabetes screening practices have changed. For this investigation, they studied members of an HMO ≥45 years of age continuously enrolled for ≥3 years, without diabetes, and assigned to primary care clinicians affiliated with a large academic health system. Of 12,772 eligible patients, at least once in 3 years, 9,941 (78%) were screened. Patients were initially screened with HbA1c 14% of the time and with glucose 86% of the time. Screening rates are high, as they noted in 2004. Investigators found that HbA1c is still used for screening less often than glucose but is more likely to lead to a clinical diagnosis.